SpyBiotech Limited
SpyBiotech is a biotechnology company focused on developing vaccines against infectious diseases, cancer, and chronic diseases using its proprietary protein superglue technology, SpyTag/SpyCatcher. The company aims to address major human health challenges worldwide with safe, effective, and scalable vaccine solutions.
Industries
Nr. of Employees
small (1-50)
SpyBiotech Limited
SpyBiotech Limited, 7600 Quorum, Oxford Business Park North, Oxford OX4 2JZ, United Kingdom
Patents
Products
HCMV VLP vaccine candidate (virus-like particle format)
A virus-like-particle vaccine candidate targeting human cytomegalovirus developed using modular antigen display on hepatitis B-derived VLP scaffolds; advanced into early-phase clinical studies.
Preclinical coronavirus RBD nanoparticle vaccine candidate
A receptor-binding-domain (RBD) nanoparticle vaccine candidate constructed by covalent attachment of RBD antigens to particulate scaffolds; demonstrated high neutralising antibody titres in preclinical studies.
HCMV VLP vaccine candidate (virus-like particle format)
A virus-like-particle vaccine candidate targeting human cytomegalovirus developed using modular antigen display on hepatitis B-derived VLP scaffolds; advanced into early-phase clinical studies.
Preclinical coronavirus RBD nanoparticle vaccine candidate
A receptor-binding-domain (RBD) nanoparticle vaccine candidate constructed by covalent attachment of RBD antigens to particulate scaffolds; demonstrated high neutralising antibody titres in preclinical studies.
Services
Provision of a modular antigen-display platform to partners via licensing and sponsored research agreements to support vaccine design and development across multiple delivery systems.
Collaborative development of vaccine candidates including preclinical testing, formulation, regulatory filings and early-phase clinical trial initiation support.
Provision of a modular antigen-display platform to partners via licensing and sponsored research agreements to support vaccine design and development across multiple delivery systems.
Collaborative development of vaccine candidates including preclinical testing, formulation, regulatory filings and early-phase clinical trial initiation support.
Expertise Areas
- Vaccine platform development (antigen display on particles)
- Virus-like particle (VLP) and nanoparticle vaccine design
- Preclinical immunology and animal-model testing
- Early-phase clinical trial execution
Key Technologies
- Covalent protein linkage for antigen display
- Virus-like particles (VLPs)
- Computationally designed protein nanoparticles
- Ferritin and other nanoparticle scaffolds
News & Updates
Oxford, UK and Cambridge, MA – (August 12, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Dr. Prakash Bhuyan as Chief Medical Officer. Dr. Bhuyan is an infectious disease specialist with over 20 years of experience in academia and industry.
Oxford, UK and Cambridge, MA – (July 23, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of enrollment in its Phase I trial of SPYVLP01, a vaccine candidate targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology.
Oxford, UK and Cambridge, MA – (June 18, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Keith Dewedoff as Chief Financial Officer (CFO). Keith brings more than 20 years of experience in the life science industry to SpyBiotech.
— Agreement to support development of a vaccine against EBV — Oxford, UK and Cambridge, MA (May 23, 2024) — SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, today announced a sponsored research agreement with The University of Oxford for the development of a vaccine.
— SpyBiotech’s lead program is targeting human cytomegalovirus (HCMV) — Oxford, UK and Cambridge, MA (December 7, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus.
— SpyBiotech’s lead program to target HCMV — Oxford, UK and Cambridge, MA (September 20, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory.
Oxford, UK and Cambridge, MA – (August 12, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Dr. Prakash Bhuyan as Chief Medical Officer. Dr. Bhuyan is an infectious disease specialist with over 20 years of experience in academia and industry.
Oxford, UK and Cambridge, MA – (July 23, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of enrollment in its Phase I trial of SPYVLP01, a vaccine candidate targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology.
Oxford, UK and Cambridge, MA – (June 18, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Keith Dewedoff as Chief Financial Officer (CFO). Keith brings more than 20 years of experience in the life science industry to SpyBiotech.
— Agreement to support development of a vaccine against EBV — Oxford, UK and Cambridge, MA (May 23, 2024) — SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, today announced a sponsored research agreement with The University of Oxford for the development of a vaccine.
— SpyBiotech’s lead program is targeting human cytomegalovirus (HCMV) — Oxford, UK and Cambridge, MA (December 7, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus.
— SpyBiotech’s lead program to target HCMV — Oxford, UK and Cambridge, MA (September 20, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory.